Linda Gillian Durrant

This inventor holds 16 USPTO granted patents and 7 published patent applications, plus 4 CIPO patents and 8 EPO patents. Top assignees: Scancell Limited, Cephalon Australia Pty. Ltd., Cancer Research Campaign Technology Limited. Active years: 2000-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Linda Gillian Durrant. Retrieved from https://idiyas.com/inventor/linda-gillian-durrant

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 7)

% Patents Active = 68.8

CIPO Patents = 4 (Patent Applications = 8)

EPO Patents = 8 (Patent Applications = 14)

Average Co-Inventor Count = 2.3

ph-index = 3

Forward Citations = 21(Granted Patents)

Location History:

Bilasby Notis, GB (2011 - 2013)
Nottingham, GB (2000 - 2022)

Company Filing History:

Cephalon Australia Pty. Ltd.

patents

1 out of 62

Cancer Research Campaign Technology Limited

patents

4. 1 out of 268

Cancer Research Technology Limited

patents

where one patent can have more than one assignee

Years Active: 2000-2026

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12643956 - BINDING MEMBERS (2026-06-02),

2. 12595313 - MODIFIED FC-REGIONS TO ENHANCE FUNCTIONAL AFFINITY OF ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF (2026-04-07),

3. 12552876 - ANTI-FUCOSYL-GM1 ANTIBODIES (2026-02-17),

4. 12458688 - Epitopes (2025-11-04),

5. 12258377 - Anti-tumour response to modified self-epitopes (2025-03-25),

6. 11382985 - Anti-tumour immune responses to modified self-epitopes (2022-07-12),

7. 10695438 - Anti-tumour immune responses to modified self-epitopes (2020-06-30),

8. 10233220 - Anti-tumour response to modified self-epitopes (2019-03-19),

9. 8742088 - Nucleic acids encoding antibodies or portions thereof comprising a heterologous T cell epitope and their use in modulating T cell responses (2014-06-03),

10. 8343490 - Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent (2013-01-01),

11. 8273349 - Binding member which binds to both lewis-Y and lewis-B haptens, and its use for treating cancer (2012-09-25),

12. 8187600 - Polypeptides capable of binding to CD64 comprising one or more heterologous T cell epitopes and their uses (2012-05-29),

13. 7915387 - Monoclonal antibody Sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent (2011-03-29),

14. 7879983 - [object Object] (2011-02-01),

15. 7267821 - [object Object] (2007-09-11),

Title: Inventor Spotlight: Linda Gillian Durrant

Introduction:

Linda Gillian Durrant, a pioneering inventor based in Nottingham, GB, has made significant contributions to the field of cancer immunotherapy with her groundbreaking innovations. With an impressive portfolio of 11 patents, Durrant continues to push the boundaries of medical research and development.

Latest Patents:

Durrant's latest patents focus on "Anti-tumour immune responses to modified self-epitopes." These patents revolve around the use of modified citrullinated enolase peptides as targets for cancer immunotherapy. These peptides serve as potential vaccines or targets for monoclonal antibody therapy, offering promising avenues for the treatment of cancer.

Career Highlights:

Throughout her illustrious career, Durrant has been associated with leading companies in the biopharmaceutical industry. She has lent her expertise to organizations such as Scancell Limited and Cephalon Australia Pty. Ltd., where she has played a pivotal role in driving innovation and product development in the field of cancer therapeutics.

Collaborations:

Durrant has collaborated closely with esteemed colleagues, including Tina Parsons and Victoria Anne Brentville. Together, they have worked tirelessly to advance the frontier of cancer immunotherapy, leveraging their collective knowledge and skills to develop novel treatment strategies that hold great promise for patients worldwide.

Conclusion:

In conclusion, Linda Gillian Durrant stands as a trailblazing inventor whose groundbreaking work in cancer immunotherapy has the potential to revolutionize the treatment landscape. Her dedication to innovation and her collaborative spirit have positioned her as a driving force in the fight against cancer, inspiring hope for a brighter and healthier future for all.

Profile summary based on public USPTO records.